Syngene International and Bristol Myers Squibb Extend Partnership
BENGALURU, India — Syngene International, a prominent contract research, development, and manufacturing organization (CRDMO), has taken a significant step forward by extending its long-term strategic collaboration with Bristol Myers Squibb through 2035. This agreement expands the scope of integrated services that span the entire drug development lifecycle.
Expanded Scope of Collaboration
The renewed partnership enhances capabilities in various critical areas, including discovery, translational sciences, pharmaceutical development, clinical trials, and data services. By broadening the scope of their collaboration, both companies aim to ensure a seamless progression from initial research phases to ultimate commercialization of innovative therapies.
An Insight from Syngene's CEO
Peter Bains, Managing Director and CEO of Syngene International, expressed enthusiasm for the extended collaboration. He stated, "Our partnership with Bristol Myers Squibb, which has flourished over 25 years, focuses on scientific excellence and operational reliability. Extending our agreement through 2035 is a pivotal strategy for both firms, as it allows us to develop new capabilities and infrastructure to meet future demands." He emphasized the strategic value this long-term perspective holds for both organizations.
Bristol Myers Squibb's Commitment to Patients
Payal Sheth, Senior Vice President of Therapeutic Discovery Sciences at Bristol Myers Squibb, shared her views on the partnership. "At Bristol Myers Squibb, our mission is patient-centric. Our collaboration with Syngene has been instrumental in meeting our scientific goals and delivering effective therapies. This extension is a testament to our dedication to advancing innovative science, integrating our research, development, and manufacturing capabilities to accelerate life-changing medicines for patients globally."
Historical Context of the Collaboration
The collaboration initially began in 1998, leading to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), which officially opened in 2009. The BBRC has become a cornerstone of Bristol Myers Squibb's R&D efforts, providing comprehensive support in areas including target identification and lead optimization. Today, this prominent center is home to around 700 Syngene scientists who function as part of Bristol Myers Squibb's global research organization.
Contributions to Drug Development and Patient Care
Since its inception, the BBRC has played a critical role in expediting the development of novel compounds from early discovery stages to human trials. This progress has resulted in shorter development timelines and cost efficiencies for Bristol Myers Squibb, allowing for quicker delivery of important therapies to patients in need.
About Syngene International
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) focuses on providing integrated research, development, and manufacturing services across a multitude of sectors, including pharmaceuticals, biotechnology, and consumer goods. With a dedicated workforce of over 8,200, including 5,600 scientists, Syngene excels in delivering innovative solutions marked by scientific integrity, robust data security, and exceptional manufacturing speeds. The company's extensive facilities, spanning over 2.5 million square feet in both India and the U.S., enable Syngene to serve around 400 global clients, including prominent multinationals.
Frequently Asked Questions
What is the duration of the renewed partnership between Syngene and Bristol Myers Squibb?
The partnership has been extended through the year 2035.
What areas are covered in the expanded collaboration?
The expanded collaboration encompasses drug discovery, translational sciences, clinical trials, and more, representing a comprehensive approach to drug development.
How many scientists does Syngene currently employ?
Syngene has over 8,200 employees, including 5,600 scientists focused on delivering high-quality research and development services.
What was established through the initial partnership in 1998?
The initial partnership led to the creation of the Biocon Bristol Myers Squibb Research and Development Center, which supports a range of R&D activities.
Why is this collaboration important for Bristol Myers Squibb?
This collaboration enhances Bristol Myers Squibb's ability to develop transformative medicines, directly benefiting patient outcomes.
